{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"52"}]}],"title":"Event free survival"},{"categories":[{"measurements":[{"groupId":"OG000","value":"59"}]}],"title":"Overall survival"}],"denoms":[{"counts":[{"groupId":"OG000","value":"68"}],"units":"Participants"}],"description":"event-free and overall survival at 12 months","groups":[{"description":"Pentostatin to be administered intravenously on days -10, -9, and -8 at a dose of 4mg/m2/day","id":"OG000","title":"Cohort I"}],"paramType":"NUMBER","reportingStatus":"POSTED","timeFrame":"every 6 mo. up to 2 years","title":"Responses to Therapy","type":"SECONDARY","unitOfMeasure":"Percent of Participants"}